109,758 Shares in Eloxx Pharmaceuticals (ELOX) Acquired by Schwab Charles Investment Management Inc.

Schwab Charles Investment Management Inc. acquired a new position in shares of Eloxx Pharmaceuticals (OTCMKTS:ELOX) in the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The fund acquired 109,758 shares of the company’s stock, valued at approximately $1,874,000. Schwab Charles Investment Management Inc. owned about 0.33% of Eloxx Pharmaceuticals at the end of the most recent quarter.

Other large investors also recently modified their holdings of the company. Menora Mivtachim Holdings LTD. purchased a new stake in Eloxx Pharmaceuticals in the 2nd quarter valued at $29,247,000. Emerald Mutual Fund Advisers Trust purchased a new stake in Eloxx Pharmaceuticals in the 2nd quarter valued at $3,414,000. Bank of New York Mellon Corp purchased a new stake in Eloxx Pharmaceuticals in the 2nd quarter valued at $1,038,000. Rhumbline Advisers purchased a new stake in Eloxx Pharmaceuticals in the 2nd quarter valued at $337,000. Finally, Strs Ohio purchased a new stake in Eloxx Pharmaceuticals in the 2nd quarter valued at $107,000.

Shares of ELOX opened at $13.83 on Friday. Eloxx Pharmaceuticals has a 1 year low of $3.90 and a 1 year high of $24.60.

Eloxx Pharmaceuticals (OTCMKTS:ELOX) last announced its quarterly earnings data on Tuesday, August 7th. The company reported ($0.42) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.39) by ($0.03).

Several analysts recently commented on ELOX shares. SunTrust Banks started coverage on shares of Eloxx Pharmaceuticals in a research report on Monday, June 25th. They issued a “buy” rating and a $26.00 price target for the company. Canaccord Genuity started coverage on shares of Eloxx Pharmaceuticals in a research report on Friday, June 29th. They issued a “buy” rating and a $24.00 price target for the company. Citigroup started coverage on shares of Eloxx Pharmaceuticals in a research report on Tuesday, July 3rd. They issued a “buy” rating and a $31.00 price target for the company. Finally, Zacks Investment Research downgraded shares of Eloxx Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Tuesday, July 3rd. One investment analyst has rated the stock with a hold rating and four have issued a buy rating to the stock. The stock has an average rating of “Buy” and an average target price of $25.25.

Eloxx Pharmaceuticals Profile

Eloxx Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing novel therapeutics for the treatment of rare and ultra-rare premature stop codon diseases. Its lead program is ELX-02, which is in Phase I clinical trial, which focuses on the treatment of cystic fibrosis and cystinosis patients with diagnosed nonsense mutations.

Featured Story: Put Option

Institutional Ownership by Quarter for Eloxx Pharmaceuticals (OTCMKTS:ELOX)

Receive News & Ratings for Eloxx Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eloxx Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply